Published 2020-01-03
Keywords
- Sickle cell trait,
- Blood donor,
- Blood transfusion
How to Cite
Copyright (c) 2020 Brazilian Journal of Health and Biomedical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Abstract
Introduction: The sickle cell trait is a genetic mutation characterized by the presence of hemoglobin S (HbS) in heterozygosis in which patients are asymptomatic, which makes them suitable for blood donation. Aim: Systematizing data related to the prevalence of the sickle cell trait among blood donors. Materials and methods: A search of the literature was conducted in May 2019 to seek articles published from 1990 and which had available online abstracts, in four electronic databases. Studies were selected with the following characteristics: (1) original work; (2) observational; (3) developed with blood donors; and (4) showing prevalence of sickle cell trait. Two independent reviewers identified the articles for inclusion in this systematic review of the literature (SRL), extracted the pre-determined data and carried out the evaluation of the works’ methodological quality. Results: Eight studies published in the last 12 years in different countries were selected to take part in this SRL. With variable sample size, all presented a cross-sectional methodology. For the detection of the presence of HbS, electrophoresis in alkaline pH was commonly used. The statistical analysis developed involved simple techniques, showing that the prevalence of blood donors with sickle cell trait ranged from 0.4% to 20.8%. The majority of studies was considered of high methodological quality. Conclusion: The prevalence of sickle cell trait among blood donors varies widely, although it may not be moderate, given that the screening of HbS has important clinical significance for the proper use of this blood component.
Metrics
References
- Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010;376:2018–31.
- Odièvre MH, Verger E, Silva-Pinto AC, et al. Pathophysiological insights in sickle cell disease. IJMR. 2011;134:532–7.
- Adekile AD. What’s new in the pathophysiology of sickle cell disease? MPP. 2013;22:311–2.
- Lei H, Karniadakis GE. Quantifying the rheological and hemodynamic characteristics of sickle cell anemia. Biophys J. 2012;102:185–94.
- Murao M, Ferraz MHC. Traço falciforme – heterozigose para hemoglobina S. Rev Bras Hematol Hemoter. 2007;29:223–5.
- Silva JEP. Traço falciforme: Uma visão para os Centros de Hemoterapia. Revista Saúde. 2010;36:23–8.
- /Antwi-Baffour S, /Asare RO, Adjei JK, et al. Prevalence of hemoglobin S trait among blood donors: a cross-sectional study. BMC research notes. 2015;8:583.
- Ministério da Saúde, B. RDC No 57, de 16 de dezembro de 2010. Available in: http://www2.ebserh.gov.br/documents/147715/0/RDC+n+57-2010+Regulamento+Sanit%C3%A1rio.pdf/b4a906a4-3763-482a-b1af-9dfc9ff2e411. Accessed in: 01/2019.
- Ministério da Saúde, B. Portaria No 158, de 04 de fevereiro de 2016. Available in: https://cevs.rs.gov.br/upload/arquivos/201612/16112320-portaria-158-de-04-02-2016.pdf. Accessed in: 01/2019.
- Moher D, Liberati A, Tetzlaff J, et al. Systematic Reviews and Meta-Analyses: The PRISMA Statement. Ann Intern Med. 2009;151:264–9.
- Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006-12.
- Martins PRJ, Pereira GDA, Pacheco KD, et al. Avaliação da freqüência de Hemoglobina A1s nos candidatos à doação de sangue no Hemocentro regional de Uberaba, no período de 1996 a 2000 – Estudo retrospectivo. Rev Med Minas Gerais. 2005;15:34–7.
- Vivas W, Rebouças D, Fabbro A, et al. Heterozigose para hemoglobinopatias em doadores de sangue do Centro de Hemoterapia de Sergipe. Rev bras hematol hemoter. 2006;28:284-7.
- Alabdulaali MK, Alayed KM, Alshaikh AF, et al. Prevalence of glucose-6-phosphate dehydrogenase deficiency and sickle cell trait among blood donors in Riyadh. AJTS. 2010;4:31.
- Moraes KCM, Galioti JB. A doença falciforme: um estudo genético-populacional a partir de doadores de sangue em São José dos Campos, São Paulo, Brasil. Rev Bras Hematol Hemoter. 2010;32:286–90.
- Egesie OJ, Egesie UG, Jatau ED, et al. Prevalence of sickle cell trait and glucose 6 phosphate dehydrogenase deficiency among blood donors in a Nigerian tertiary hospital. Afr J of Biomed Res. 2013;16:143–8.
- Lidani KCF, Barros RF, Bovo F. Relationship between the prevalence of hemoglobin S and the ethnic background of blood donors in Paraná state. JBPML. 2015;51:212–7.
- Adu P, Simpong DL, Takyi G, et al. Glucose-6-phosphate dehydrogenase deficiency and sickle cell trait among prospective blood donors: A cross-sectional study in Berekum, Ghana. Adv Hematol. 2016;1:1-7.
- Bastos JLD, Duquia RP. Erratum para: Um dos delineamentos mais empregados em epidemiologia: Estudo transversal. Sci Med. 2013;23:229–32.
- Grilo KTM, Pasqualin MAJ, Barbosa VL. HEMOTERAPIA: Artigos científicos de conclusão de curso de pós-graduação lato sensu em Hemoterapia. Curitiba: SESA: SETI/UEM, 2015.
- Prudêncio BCAB, Covas DT, Bonini-domingos CR. Comparação de metodologia utilizada para a detecção de Hemoglobina S (HbS) em doadores de sangue. Rev Bras Hematol Hemoter. 2000;22:99–109.
- Ministério da Saúde, B. RDC No 153, de junho de 2004. Available in: http://www.sbpc.org.br/upload/noticias_ gerais/320100416113458.pdf. Accessed in: 01/2019.
- Roseff SD, Bethesda MD. American Association Blood Banks. Transfusão Pediátrica: Manual para médicos.1a Edição. 2006.